BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Summit Therapeutics

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a type of lung cancer.

US FDA lifts partial clinical hold on BioNTech cancer drug study

Transmedics Group Inc

Walgreens

I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond.

2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid

Vertex Pharmaceuticals

I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion.

2 No-Brainer Stocks to Buy Before the End of 2024

On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE  BNTX.

Why Is BioNTech Stock Trading Higher On Friday?

Intel

Coca-Cola

McCormick

Occidental Petroleum

The end of the year can spur myriad feelings when deciding which stocks are the best buys.

5 Top Stocks to Buy in December

Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line.

BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.

BioNTech SE ADR   (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance,  after an Evercore ISI upgrade to "outperform" from "in-line.

Analysts Turn Bullish on BioNTech Stock Amid Volatility

The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases.

BioNTech and Moderna at vanguard of new treatment wave - but which is best?

AstraZeneca

Eli Lilly

Novavax

Novo Nordisk

Pfizer

In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.

Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head

GlaxoSmithKline

Inovio Pharmaceuticals

Merck

Sanofi

Valneva SE

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Over the last few months, much has been said and even more has been speculated on when it comes to how the outcome of the 2024 U.S. presidential election will impact the economy, both global and domestic, as well as wider economic conditions.

Shot Down: Vaccine stocks tumble with RFK Jr. as Health Secretary

President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.

Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS

Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK

Pharma shares hit as Trump picks RFK Jr to lead health department

Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services.

Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up

German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.

BioNTech buys China's Biotheus to support oncology strategy

MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) --  BioNTech SE  (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential

BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved revenues and profit, largely driven by its COVID-19 vaccine, Comirnaty, which remains a significant revenue source. Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a “Hold” rating.

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

HCA Healthcare

Humana

Tenet Healthcare

Universal Health Services

UnitedHealth Group

Health Care Select Sector SPDR Fund

Investors are worried about what a Trump administration means for hospital operators and vaccine makers, but are optimistic about the fate of Medicare Advantage plan providers.

Why most healthcare stocks are falling with Trump's win, with some exceptions

BioNTech SE (NASDAQ:BNTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Daina Graybosch - Leerink Partners Suzanne van Voorthuizen - VLK Terence Flynn - Morgan Stanley Yaron Werber - TD Cowen Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Luke Shumway - BMO Capital Markets Ellie Merle - UBS Yifeng Liu - HSBC Bank Plc Simon Baker - Redburn Atlantic Manos Mastorakis - Deutsche Bank Jay Olson - Oppenheimer Operator Welcome to BioNTech's Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.

BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript

BioNTech SE reported a surprising profit for the third quarter, achieving earnings of €0.81 ($0.88) per diluted share, far exceeding analyst expectations of a loss of €1.84. The Mainz, Germany-based company also posted sales of €1.2 billion, nearly three times higher than anticipated.

BioNTech surprises with Q3 profit driven by strong vaccine sales

On Monday, BioNTech SE BNTX reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 million euros a year ago.

BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3

BioNTech stock jumped on Monday after the German company reported unexpected profit and walloped sales expectations for the third quarter. The post BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook appeared first on Investor's Business Daily.

News for BioNTech SE Stock (BNTX)